Search Results

Aceclofenac and Paracetamol Tablets: Uses, Side Effects and Top Brands in India (2026) - Vibcare Pharma

Aceclofenac and Paracetamol Tablets: Uses, Side Effects and Top Brands in India (2026)

Vibcare Pharma

09/10/26

  • Updated 9 October 2026
  • Reviewed by Sudhanshu Singhal
  • 20 min read
  • 34 sources
46Vibcare aceclofenac + paracetamol products, all listed below
15compositions and strengths in the Vibcare range
BrandCompanyCommon pack and MRP (Rs)
Zerodol PIpca Laboratories LtdStrip of 10 tablets — ₹75.94 (1mg.com, page stamp 09 Oct 2026)
Hifenac PIntas Pharmaceuticals LtdStrip of 15 tablets — ₹117.5 (1mg.com, page stamp 09 Oct 2026). Note: the 1mg listing shows 100 mg + 325 mg, while the Intas leaflet on file (27/09/15) describes Hifenac-P as 100 mg + 500 mg; check the pack in hand.
Aceclo PlusAristo Pharmaceuticals Pvt LtdStrip of 15 tablets — ₹117 (1mg.com, page stamp 09 Oct 2026)
Dolokind PlusMankind Pharma LtdStrip of 15 tablets — ₹85.35 (1mg.com, page stamp 09 Oct 2026)
Dolowin PlusMicro Labs LtdStrip of 10 tablets — ₹83.4 (1mg.com, page stamp 09 Oct 2026)
Acenac-PMedley PharmaceuticalsStrip of 15 tablets — ₹122 (1mg.com, page stamp 09 Oct 2026)
Acemiz PlusLupin LtdNot listed
Aldigesic P 100 mg/325 mgAlkem Laboratories LtdNot listed
Movexx PlusCipla LtdNot listed
acimol 100 mg/325 mgLeeford Healthcare LtdNot listed
Zulu-P, Acyclosure P, AcegesicTorrent PharmaceuticalsNot listed
Zerodol-SP (100 mg + 325 mg + serratiopeptidase 15 mg)Ipca Laboratories LtdStrip of 10 tablets — ₹150.85 (1mg.com, page stamp 09 Oct 2026)
Dolowin-MR (100 mg + chlorzoxazone 250 mg + 325 mg)Micro Labs LtdStrip of 10 tablets — ₹108.7 (1mg.com, page stamp 09 Oct 2026)
Dolowin TC 4 (aceclofenac 100 mg + thiocolchicoside 4 mg)Micro Labs LtdStrip of 10 tablets — ₹196.8 (1mg.com, page stamp 09 Oct 2026)
Dolowin-SR (aceclofenac 200 mg SR)Micro Labs LtdStrip of 10 SR tablets — ₹96.56 (1mg.com, page stamp 09 Oct 2026)
MRPs as listed on the Indian e-pharmacy pages named under Sources, read 9 October 2026; prices change, so check the pack. Listed in no particular order unless the text says otherwise.

All MRPs above are taken from 1mg.com listings carrying the page stamp "Last updated on 09 Oct 2026"; 1mg notes "MRP may vary by batch", and MRPs change over time and between batches.

What is aceclofenac + paracetamol (and the SP, MR and thiocolchicoside versions)?

It is a pain-relief tablet that combines two medicines: the NSAID aceclofenac and the analgesic/antipyretic paracetamol. Indian manufacturers sell it mainly as 100 mg + 325 mg film-coated tablets, and versions with an added muscle relaxant or enzyme are sold under separate brands.

Aceclofenac

Aceclofenac is a non-steroidal agent with marked anti-inflammatory and analgesic properties. Its mode of action is largely based on the inhibition of prostaglandin synthesis, and it is a potent inhibitor of the enzyme cyclo-oxygenase (Preservex SmPC, section 5.1).

The UK regulator MHRA notes that aceclofenac has little pharmacological activity itself; its main mode of action is through its metabolites, which include diclofenac and 4'-hydroxy diclofenac. After oral dosing it is rapidly and completely absorbed as unchanged drug, with peak plasma levels about 1.25 to 3.00 hours after ingestion and a mean plasma elimination half-life of around 4 hours.

Paracetamol

Paracetamol is a mild analgesic and antipyretic recommended for most painful and febrile conditions (UK SmPC, sections 4.1 and 5.1). It has only weak anti-inflammatory properties, and its mechanism of action is not fully understood.

What each combination partner adds

  • Serratiopeptidase (SP) is a proteolytic enzyme prescribed in surgery, orthopaedics, otorhinolaryngology, gynaecology and dentistry for its anti-inflammatory, anti-edemic and analgesic effects. A 2013 systematic review of 24 clinical studies states that the supporting evidence is based on clinical studies of poor methodology, that existing scientific evidence is insufficient to support its use as an analgesic and health supplement, and that data on long-term safety is lacking.
  • Chlorzoxazone (MR) is a centrally-acting agent for painful musculoskeletal conditions, acting primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex arcs (US FDA-registered label). The label adds that its mode of action may be related to its sedative properties and that it does not directly relax tense skeletal muscles in man.
  • Thiocolchicoside is used as a muscle relaxant in the treatment of painful muscular conditions and is thought to act on receptors in the nervous system involved in the regulation of muscle function (EMA, 2013).

Forms and strengths sold in India

Examples listed on Indian e-pharmacies include 100 mg + 325 mg; 100 mg + 325 mg + serratiopeptidase 15 mg; 100 mg + chlorzoxazone 250 mg + 325 mg; and aceclofenac 100 mg + thiocolchicoside 4 mg. Three-drug tablets with thiocolchicoside are listed as 4 mg / 100 mg / 325 mg per tablet.

Aceclofenac alone is sold as 100 mg tablets and as sustained-release 200 mg tablets. One 100/500 version (100 mg + 500 mg) is described in an Intas leaflet dated 27/09/15. These listings are e-pharmacy pages carrying the stamp 09 Oct 2026, not regulatory documents.

What is it used for?

Each source states its own labelled use, and the wording differs between them; the Indian CDSCO-approved indication text for the 100/325 combination could not be verified from a primary CDSCO document. The Indian manufacturer information sheet for the 100 mg + 325 mg combination gives the indication as "For acute painful conditions in adults only", and adds that the fixed-dose combination should be administered under the supervision of physicians.

The UK licensed indication for aceclofenac (Preservex) is relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis; the MHRA repeats these three conditions. The Intas leaflet for the 100 mg + 500 mg version states it is indicated for the treatment of acute painful inflammatory conditions with or without associated fever. These are source-specific labelled indications and may not match the CDSCO-approved indication for Indian brands.

The paracetamol SmPC recommends paracetamol for most painful and febrile conditions, for example headache including migraine, toothache, neuralgia, colds and influenza, sore throat, backache, rheumatic pain and dysmenorrhoea. Chlorzoxazone is described in its FDA label as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Thiocolchicoside by mouth or injection is recommended only as adjuvant treatment for acute muscle contractures in spinal pathology, for adults and adolescents from 16 years of age, and not for longer-term treatment of chronic conditions (EMA, 2013).

A 2024 meta-analysis of 22 randomised studies found paracetamol plus aceclofenac reduced pain more than aceclofenac alone in osteoarthritis at the immediate term (mean difference −4.7, 95% CI −8.3 to −1.2; moderate-certainty evidence); the authors conclude that low-to-moderate quality evidence supports some paracetamol plus NSAID combinations for short-term pain relief with no increased risk of harm versus the non-paracetamol comparator.

Dose as stated in the labels

The dose differs between labels and between brands, so follow the dose your doctor prescribes and the leaflet in your pack; the figures below are the usual adult dose stated in each label quoted and are not personal dose advice.

Aceclofenac alone (UK SmPC, Preservex)

The usual adult dose stated in the UK label is 200 mg daily, taken as two separate 100 mg doses, one tablet in the morning and one in the evening. It adds that undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms.

For children, there are no clinical data on the use of Preservex in children and therefore it is not recommended for use in children. In the elderly, pharmacokinetics are not altered, so no dose or frequency change is considered necessary, though the lowest effective dose and shortest time are advised with regular monitoring for gastrointestinal bleeding.

In mild renal impairment there is no evidence the dose needs changing, but as with other NSAIDs caution should be exercised. In hepatic impairment some evidence suggests the dose should be reduced, and an initial daily dose of 100 mg is suggested. The label says the tablets are to be taken preferably with or after food, swallowed whole with a sufficient quantity of liquid.

Indian combination labels

The Torrent information sheet for aceclofenac 100 mg + paracetamol 325 mg states: "The daily recommended dose is one tablet daily for adults" and "It is recommended to take the daily dose in one single intake"; the tablet is swallowed whole with liquid and may be taken with or without food. The Intas leaflet for the 100 mg + 500 mg version states one tablet twice daily, with the maximum recommended dose being two tablets daily; in impaired hepatic function the dose is reduced to one tablet daily.

Both Indian sheets state that there are no clinical data in children: Torrent says the combination is not recommended for use in children, and Intas states there are no clinical data available on the use of aceclofenac in children. In chronic alcoholism, the Torrent sheet says the daily dose of paracetamol should not exceed 2000 mg.

Paracetamol general limits and other components

  • The UK paracetamol label (500 mg tablets) states that adults, the elderly and children over 16 take two tablets every four hours as required, not more than eight tablets in 24 hours and no more than four doses in any 24 hours, and not for more than 3 days without consulting a doctor.
  • MedlinePlus states as a general paracetamol caution: "do not take more than 4000 mg of acetaminophen per day from all sources" and do not take more than one product containing acetaminophen at a time. This is not a dose recommendation for the aceclofenac + paracetamol combination; the specific product label and your doctor's instructions take precedence.
  • The chlorzoxazone FDA label dose covers 375 mg and 750 mg US tablets only (one 375 mg tablet three or four times daily) and is not dosing guidance for the Indian 250 mg combination tablet.
  • The EMA states a maximum oral dose of thiocolchicoside 8 mg every 12 hours for no more than 7 consecutive days.
  • No regulator-issued label dose for serratiopeptidase was found; one 2023 study used a tablet of aceclofenac 100 mg, paracetamol 325 mg and serratiopeptidase 15 mg twice daily for five days after molar surgery.

Side effects

The most commonly observed adverse events with aceclofenac are gastrointestinal in nature. Frequencies below come from the Preservex SmPC: common means 1 in 100 to less than 1 in 10, uncommon 1 in 1,000 to less than 1 in 100, rare 1 in 10,000 to less than 1 in 1,000, and very rare less than 1 in 10,000.

  • Common: dizziness; dyspepsia, abdominal pain, nausea, diarrhoea; hepatic enzyme increased.
  • Uncommon: flatulence, gastritis, constipation, vomiting, mouth ulceration; pruritus, rash, dermatitis, urticaria; blood urea increased, blood creatinine increased.
  • Rare: melaena, gastrointestinal haemorrhage, gastrointestinal ulceration; anaemia; anaphylactic reaction (including shock) and hypersensitivity; hypertension; cardiac failure; dyspnoea; visual disturbance; angioedema.
  • Very rare: intestinal perforation, haematemesis, pancreatitis, exacerbation of Crohn's disease and ulcerative colitis, stomatitis; hepatic injury including hepatitis and jaundice; renal failure and nephrotic syndrome; bone marrow depression, thrombocytopenia, neutropenia, haemolytic anaemia; severe mucocutaneous skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis; purpura; bronchospasm.

Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal and particularly in the elderly, may occur. Serious skin reactions, some of them fatal, have been reported, with the highest risk early in therapy; the label says to stop at the first sign of rash, mucosal lesions or hypersensitivity. NSAIDs may cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure, with effects on renal function usually reversible on withdrawal, and hepatitis may occur without prodromal symptoms.

Cardiovascular risk

Oedema, hypertension and cardiac failure have been reported with NSAIDs. The Preservex SmPC states that diclofenac data point to an increased risk of general arterial thrombotic events (for example myocardial infarction or stroke, particularly at high doses or in long treatment), and epidemiological data also found an increased risk of acute coronary syndrome and myocardial infarction with aceclofenac. An EU review estimated about 3 extra heart attacks per year per 1,000 people at moderate risk treated with diclofenac (the metabolite); that figure is for diclofenac, not aceclofenac.

Paracetamol, chlorzoxazone and thiocolchicoside

Paracetamol can cause hypersensitivity including skin rash; very rare cases of serious skin reactions are reported. These are not all possible side effects; the product leaflet has the full list. Liver damage is possible in adults who have taken 10 g or more, and 5 g or more may cause liver damage if the patient has risk factors; MedlinePlus warns that taking too much acetaminophen can cause liver damage serious enough to require liver transplantation or cause death.

Chlorzoxazone: serious, including fatal, hepatocellular toxicity has been reported rarely, and the mechanism appears to be idiosyncratic and unpredictable; drowsiness, dizziness, light-headedness, malaise or overstimulation may occur. Thiocolchicoside: the EMA reports that a metabolite may be associated with aneuploidy in dividing cells at exposures not much greater than those achieved with maximum recommended oral doses, which is a risk factor for harm to the developing fetus and reduced male fertility.

Who should not take it, and interactions

Aceclofenac is contraindicated in several groups, and the list below is taken from the Preservex SmPC and the MHRA advice.

  • Hypersensitivity to aceclofenac or any excipient, or prior hypersensitivity (asthma, rhinitis, angioedema or urticaria) to ibuprofen, aspirin or other NSAIDs.
  • Active peptic ulcer or haemorrhage, or a history of recurrent ulcer or haemorrhage (two or more distinct episodes), or gastrointestinal bleeding or perforation related to previous NSAID therapy.
  • Hepatic failure and renal failure; active bleeding or bleeding disorders.
  • Established congestive heart failure (NYHA II–IV), ischaemic heart disease, peripheral arterial disease or cerebrovascular disease.
  • Varicella (chickenpox), because of possible serious skin and soft-tissue infection complications.

Caution and monitoring are advised in bronchial asthma, hepatic porphyria, systemic lupus erythematosus or mixed connective tissue disease, and Crohn's disease or ulcerative colitis. The MHRA advises starting aceclofenac only after careful consideration of risk factors such as hypertension, hyperlipidaemia, diabetes mellitus and smoking.

Pregnancy and breastfeeding as the labels state

Aceclofenac is contraindicated in the third trimester, and in the first and second trimester it should not be given unless clearly necessary; from the 20th week it may cause oligohydramnios. It may impair female fertility and is not recommended in women attempting to conceive, and use should be avoided in pregnancy and lactation unless the potential benefits outweigh the possible risks to the foetus.

Paracetamol can be used in pregnancy if clinically needed, at the lowest effective dose for the shortest possible time and at the lowest possible frequency; it is excreted in breast milk but not in a clinically significant amount. MedlinePlus records a September 2025 FDA safety notice that taking acetaminophen while pregnant may be associated with neurological conditions in children, while adding that no evidence to date has shown causation. The Intas leaflet states the drug is not recommended in pregnant and breastfeeding women and is contraindicated in the last three months of pregnancy.

Thiocolchicoside is contraindicated in pregnancy, lactation, women of childbearing potential not using contraception, children, and for chronic conditions; the EMA recommends it only as adjuvant treatment for acute muscle contractures in spinal pathology, for adults and adolescents from 16 years of age. Safe use of chlorzoxazone in pregnancy has not been established.

Key interactions

  • Avoid concomitant use of two or more NSAIDs (including aspirin), and avoid combining with COX-2 selective inhibitors, as this increases adverse effects including gastrointestinal bleeding.
  • NSAIDs may enhance the effects of anticoagulants such as warfarin; corticosteroids, antiplatelet agents and SSRIs raise gastrointestinal bleeding and ulcer risk.
  • ACE inhibitors, angiotensin II receptor antagonists and diuretics may have reduced effect, with higher risk of acute renal insufficiency in dehydrated or elderly patients.
  • This list is not complete: read the product leaflet and tell your doctor or pharmacist about every medicine you take.
  • Digoxin and lithium levels may rise; methotrexate within 24 hours of an NSAID raises methotrexate levels and toxicity; quinolone antibiotics raise the risk of convulsions.
  • Do not take any other paracetamol-containing products; the Torrent sheet repeats this advice for the combination.

Alcohol

The Torrent information sheet states that alcohol should not be used during treatment with paracetamol, and in chronic alcoholism the daily paracetamol dose should not exceed 2000 mg. MedlinePlus says not to take acetaminophen if you drink three or more alcoholic drinks every day, and the chlorzoxazone label notes that alcohol or other CNS depressants may have an additive effect.

Rules in India

The Torrent information sheet for the 100 mg + 325 mg combination is headed "To be sold by retail on the prescription of R.M.P. only"; the CDSCO Schedule H status of later brands was not verified. Paracetamol appears in NLEM 2022, while aceclofenac does not.

  • NLEM 2022 lists paracetamol in section 2.1.5 at levels of care P, S and T: tablets 500 mg and 650 mg, oral liquids 120 mg/5 mL, 125 mg/5 mL, 250 mg/5 mL, injection 150 mg/mL, suppositories 80 mg and 170 mg.
  • The words aceclofenac, chlorzoxazone, thiocolchicoside and serratiopeptidase do not appear in the 135-page NLEM 2022 list; the NSAIDs listed under 2.1 are acetylsalicylic acid, diclofenac, ibuprofen, mefenamic acid and paracetamol.
  • The Schedule H list in the Drugs and Cosmetics Rules 1945 (edition amended up to 31 Dec 2016, hosted by CDSCO) names chlorzoxazone (entry 109), serratiopeptidase (entry 451), thiocolchicoside (entry 494) and diclofenac sodium/potassium/acid (entry 149). In that edition aceclofenac does not appear by name in Schedule H and paracetamol is not in Schedule H; later amendments were not checked.
  • DPCO 2013 paragraph 20 governs non-scheduled formulations: the Government monitors MRPs and no manufacturer may increase the MRP of a drug by more than ten per cent of the MRP during the preceding twelve months.

No NPPA ceiling price for aceclofenac or the 100/325 combination was located. For paracetamol 500 mg tablets, a Department of Pharmaceuticals speaking order records ₹0.94 per tablet on 14 June 2013, revised to ₹1.01 on 2 March 2016, and fixed at ₹0.83 per tablet by NPPA order S.O. 1951(E) dated 2 June 2016; these are historical figures and the current ceiling price was not located from a primary NPPA document. A secondary source reports that an NPPA order of 25 March 2026 fixed revised ceiling prices for scheduled formulations effective 1 April 2026, with a wholesale price index increase of 0.64956% (2025 over 2024), exclusive of GST.

Top brands in India

Several companies market the 100 mg + 325 mg combination in India, and the table at the top of this page lists the brands named in the source listings, with their companies, common packs and MRPs. No sales rank is claimed for these brands except where a published source is cited, and readers should compare packs and prices at the time of purchase.

Two published sales references exist. An Ipca corporate presentation of December 2019 states an all-India IQVIA rank of 21st (MAT Dec 2019) and says three Ipca brands were among the top 300 brands, naming HCQS, Zerodol-P and Zerodol-SP. BioSpectrum India, citing PHARMARACK data and published 11 February 2026, reports Zerodol SP monthly sales of ₹67 crore in January 2026, with value growth of 31.2% and unit growth of 22.4%; the article does not state the composition. No published sales-value ranking was found for Hifenac P, Dolokind Plus, Aceclo Plus, Dolowin Plus or other brands in this group.

The Vibcare range

Vibcare Pharma markets a wide range of aceclofenac-based tablets across its divisions, covering the plain 100 mg + 325 mg tablet, versions with serratiopeptidase 10 mg or 15 mg, chlorzoxazone 250 mg or 500 mg, thiocolchicoside 4 mg, tizanidine 2 mg, rabeprazole 20 mg, drotaverine, trypsin–chymotrypsin and cold-relief combinations, plus aceclofenac 200 mg sustained-release tablets and a 50 mg + 125 mg suspension. Packs come in 10x10 alu-alu and blister and 10x2x10 blister forms.

Aceclofenac 100 mg + Paracetamol 325 mg

4 divisions

Aceclofenac 100 mg + Paracetamol 325 mg + Cetirizine 10 mg + Phenylephrine 5 mg + Caffeine 25 mg

3 divisions

Aceclofenac 100 mg + Paracetamol 325 mg + Chlorzoxazone 250 mg

4 divisions

Aceclofenac 100 mg + Paracetamol 325 mg + Chlorzoxazone 500 mg

Prima

Aceclofenac 100 mg + Paracetamol 325 mg + Serratiopeptidase 10 mg

Prima

Aceclofenac 100 mg + Paracetamol 325 mg + Serratiopeptidase 15 mg

4 divisions

Aceclofenac 100 mg + Paracetamol 325 mg + Thiocolchicoside 4 mg

4 divisions

Aceclofenac 100 mg + Paracetamol 325 mg + Trypsin Chymotrypsin 50000Au

2 divisions

Aceclofenac 100 mg + Thiocolchicoside 4 mg

4 divisions

Aceclofenac 100 mg + Tizanidine 2 mg

Prima

Aceclofenac 200Mg Sr 200 mg

2 divisions

Aceclofenac 200 mg + Cyclobenzaprine 15 mg

Genvimax

Aceclofenac 200 mg + Rabeprazole 20 mg

4 divisions

Aceclofenac 50 mg + Paracetamol 125 mg

Evermed

Drotaverine 80 mg + Aceclofenac 100 mg

4 divisions

Vibcare Pharma appoints PCD franchise partners district by district, with one partner per district and monopoly rights confirmed in writing.

For distributors and entrepreneurs

Add aceclofenac + paracetamol to your range

Vibcare appoints one PCD franchise partner per district, with monopoly rights confirmed in writing. Trade rates for every product are on its product page.

Frequently asked questions

Is aceclofenac + paracetamol a painkiller?

Yes. Aceclofenac is a non-steroidal anti-inflammatory drug with anti-inflammatory and analgesic properties, and paracetamol is a mild analgesic and antipyretic. The Indian manufacturer information sheet for the 100 mg + 325 mg combination gives its use as "For acute painful conditions in adults only", and states it should be administered under the supervision of physicians.

Can it be taken for fever?

Paracetamol is an antipyretic and is recommended in its UK label for most painful and febrile conditions, and the Intas leaflet for the 100 mg + 500 mg version lists acute painful inflammatory conditions "with or without associated fever". However, the UK aceclofenac label lists only osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and the Torrent sheet does not mention fever. Ask your doctor what is suitable for your symptoms, and take prescription medicines only as prescribed.

Can I take it on an empty stomach?

The UK aceclofenac label says the tablets are to be taken preferably with or after food and swallowed whole with a sufficient quantity of liquid, while the Torrent sheet says the combination tablet may be taken with or without food. Because NSAIDs can cause peptic ulcers, perforation or gastrointestinal bleeding at any time, follow the instructions in your pack and the advice of your doctor.

Is it safe for the kidneys?

It is contraindicated in renal failure, and NSAIDs may cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure, with effects usually reversible on withdrawal. The UK label advises caution in mild renal impairment and notes higher risk with impaired kidney function, heart or liver problems, diuretics, dehydration and old age, with monitoring of kidney function.

Can I take it with other painkillers (ibuprofen, diclofenac, aspirin, or more paracetamol)?

No — the labels advise avoiding concomitant use of two or more NSAIDs including aspirin, as this increases adverse effects including gastrointestinal bleeding, and to avoid combining with COX-2 selective inhibitors. Do not take any other paracetamol-containing product at the same time. Follow your doctor's prescription and the dose stated in the product leaflet; any general paracetamol ceiling (such as the 4000 mg figure in MedlinePlus) is not a dose recommendation for this combination. Always tell your doctor about every medicine you are taking.

Can I drink alcohol with it?

The Indian combination sheet states that alcohol should not be used during treatment with paracetamol, and caps paracetamol at 2000 mg a day in chronic alcoholism. MedlinePlus says not to take acetaminophen if you drink three or more alcoholic drinks every day, and the chlorzoxazone label notes that alcohol may have an additive sedative effect.

Is it safe for people with heart disease or high blood pressure?

Aceclofenac is contraindicated in established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease and NYHA II–IV heart failure, and patients in these groups should be switched at their next routine appointment. In people with hypertension, hyperlipidaemia, diabetes mellitus or who smoke, the MHRA advises starting only after careful consideration of these risk factors.

Can pregnant women take it?

Aceclofenac is contraindicated in the third trimester and should not be given in the first and second trimesters unless clearly necessary; it may impair female fertility and is not recommended in women attempting to conceive. Paracetamol may be used in pregnancy if clinically needed at the lowest effective dose for the shortest possible time, and the Intas leaflet states the combination is not recommended in pregnant and breastfeeding women. Speak to a doctor before taking any medicine in pregnancy.

Sources

Show all 34 sources
  1. electronic Medicines Compendium – Preservex 100 mg film-coated tablets SmPC
  2. MHRA – Aceclofenac (Preservex): updated cardiovascular advice
  3. electronic Medicines Compendium – Paracetamol 500 mg Tablets SmPC
  4. MedlinePlus (US NLM) – Acetaminophen
  5. PubMed – Bhagat et al., International Journal of Surgery 2013: Serratiopeptidase systematic review
  6. PubMed – Journal of Maxillofacial and Oral Surgery 2018: serratiopeptidase after impacted-molar surgery
  7. DailyMed (US NLM) – Chlorzoxazone tablet label
  8. MedlinePlus (US NLM) – Chlorzoxazone
  9. European Medicines Agency – Recommendation on thiocolchicoside, 22 Nov 2013
  10. EMA/PRAC – Cardiovascular precautions for diclofenac, 14 June 2013
  11. PubMed – Drugs 2024: paracetamol plus NSAID combinations meta-analysis
  12. PubMed – Cureus 2023: trial of aceclofenac, paracetamol and serratiopeptidase after molar surgery
  13. Torrent Pharmaceuticals – Zulu-P information sheet (aceclofenac 100 mg + paracetamol 325 mg)
  14. Torrent Pharmaceuticals – Acyclosure P information sheet
  15. Torrent Pharmaceuticals – Acegesic information sheet
  16. Intas Pharmaceuticals – Hifenac-P patient leaflet, 27/09/15
  17. 1mg.com – Zerodol P tablet listing
  18. 1mg.com – Hifenac P tablet listing
  19. 1mg.com – Aceclo Plus tablet listing
  20. 1mg.com – Dolokind Plus tablet listing
  21. 1mg.com – Dolowin Plus tablet listing
  22. 1mg.com – Acenac-P tablet listing
  23. 1mg.com – substitute listings for the 100 mg + 325 mg combination
  24. 1mg.com – Zerodol-SP tablet listing
  25. 1mg.com – Dolowin-MR tablet listing
  26. 1mg.com – Dolowin TC 4 tablet listing
  27. 1mg.com – Dolowin-SR tablet listing
  28. National Health Mission / NHSRC – National List of Essential Medicines 2022
  29. CDSCO – Drugs and Cosmetics Rules 1945 (amended up to 31 Dec 2016)
  30. NPPA – Drugs (Prices Control) Order 2013
  31. Department of Pharmaceuticals – speaking order on paracetamol 500 mg tablet price
  32. TeamLease RegTech – NPPA revised ceiling prices effective 1 April 2026
  33. Ipca Laboratories – corporate presentation, December 2019
  34. BioSpectrum India – brand growth in January 2026 (PHARMARACK data)
For distributors and entrepreneurs

Add aceclofenac + paracetamol to your range

Vibcare appoints one PCD franchise partner per district, with monopoly rights confirmed in writing. Trade rates for every product are on its product page.

About this article. Written by the Vibcare Pharma team from the sources listed above and reviewed by Sudhanshu Singhal, Director & Co-Founder, Vibcare Pharma. Figures are as published on the dates shown. Medical information here is general information, not a substitute for advice from a doctor.

Copy Link

Looking into the future of healthcare

Contact

Plot No 4, HSIIDC IT PARK, Sector 22,Panchkula, Haryana, India 134109

Phone: 9888988858

Business Hours

Mon-Sat: 9AM to 6PM

Business Enquiry

Request a callback to get more information about becoming a Partner